Top Page
Oncopeptides AB
(ONCO)
Oncopeptides AB (ONCO) vs. iShares MSCI Sweden ETF (EWD)
Oncopeptides AB Business Overview & Revenue Model
Oncopeptides AB Earnings Call Summary
Oncopeptides AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.87M | 31.65M | 35.22M | 8.36M | 118.30M | 0.00 |
| Gross Profit | 49.13M | 28.98M | 36.30M | 8.35M | 65.17M | -14.40M |
| EBITDA | -260.65M | -261.81M | -231.62M | -319.62M | -1.40B | -1.58B |
| Net Income | -267.18M | -284.61M | -249.11M | -337.95M | -1.43B | -1.59B |
Balance Sheet | ||||||
| Total Assets | 136.44M | 244.19M | 238.38M | 385.32M | 439.38M | 946.76M |
| Cash, Cash Equivalents and Short-Term Investments | 70.15M | 178.54M | 173.44M | 344.51M | 364.30M | 852.48M |
| Total Debt | 124.23M | 141.72M | 126.16M | 9.54M | 14.19M | 19.36M |
| Total Liabilities | 203.32M | 189.91M | 181.60M | 91.03M | 228.51M | 369.86M |
| Stockholders Equity | -66.88M | 54.28M | 56.78M | 294.29M | 210.87M | 576.90M |
Cash Flow | ||||||
| Free Cash Flow | -324.71M | -260.57M | -279.61M | -423.02M | -1.52B | -1.31B |
| Operating Cash Flow | -324.71M | -260.57M | -279.49M | -420.51M | -1.52B | -1.30B |
| Investing Cash Flow | 496.00K | 496.00K | -116.00K | -2.51M | -339.00K | -20.13M |
| Financing Cash Flow | 11.91M | 263.81M | 106.89M | 392.40M | 1.03B | 1.32B |
Oncopeptides AB Technical Analysis
Oncopeptides AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.28B | ― | ― | ― | 131.20% | 32.28% | |
47 Neutral | €1.04B | -3.56 | -35.03% | ― | ― | 25.14% | |
43 Neutral | €217.39M | 1.17 | -16.90% | ― | 4.64% | ― | |
43 Neutral | €390.59M | -2.68 | -79.60% | ― | ― | 31.62% | |
32 Underperform | €97.31M | -1.80 | -1291.15% | ― | ― | 28.54% | |
31 Underperform | kr815.45M | -4.15 | 81.19% | ― | ― | ― |
Oncopeptides AB Corporate Events
Oncopeptides AB announced that a panel of multiple myeloma experts has endorsed the use of its drug Pepaxti, also known as melflufen, for treating relapsed, refractory multiple myeloma. The expert consensus, published in the Annals of Hematology, emphasizes Pepaxti’s effectiveness for heavily pretreated patients, including the elderly and those with high-risk disease profiles, reinforcing its role as a critical treatment option. This endorsement strengthens Pepaxti’s market positioning and confirms its utility across diverse patient subgroups, aligning with findings from pivotal studies and real-world applications.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB’s recent earnings call presented a balanced sentiment, highlighting significant revenue growth and a strong cash position, while also acknowledging challenges such as a net loss and delays in securing a Japanese partnership. The call reflected a mix of optimism due to positive growth indicators and caution due to existing challenges.
Oncopeptides AB reported a significant growth in net sales for Q3 2025, with a 174% increase year over year, driven by its key European markets. The company is progressing towards becoming cash flow positive by the end of 2026 and is in negotiations with potential partners in Japan. The period also saw the oversubscription of a rights issue and the inclusion of their drug Pepaxti in European guidelines, which could enhance their market positioning and stakeholder confidence.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB announced that a collaborative study on NK cell engagers, part of the Eurostars NKENGAGE project, will be presented at the American Society of Hematology Annual Meeting. The study explores a novel immunotherapeutic approach for multiple myeloma using NK cells, showing promising preclinical results with reduced toxicity compared to T-cell strategies. This recognition at ASH highlights Oncopeptides’ expansion beyond peptide-drug conjugates and its potential to address unmet needs in cancer treatment.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB announced a change in the number of votes due to the conversion of class C shares to ordinary shares as part of its incentive program. This adjustment reflects the company’s ongoing efforts to align its share structure with its strategic goals, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB announced the upcoming release of its Q3 2025 financial report, scheduled for November 5, 2025. The company will host a webcast and Q&A session for investors, analysts, and media, led by CEO Sofia Heigis and CFO Henrik Bergentoft. This event provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market positioning.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB announced it will host a Capital Markets Update on November 13, 2025, to provide insights into its strategic direction and expanding role in the treatment of multiple myeloma. The event will feature presentations from international experts and company leaders, offering clinical, scientific, and market perspectives, which may influence the company’s market positioning and investment appeal.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB announced the publication of three case reports in the Journal of Cancer Research and Clinical Oncology, showcasing long-lasting responses to their drug Pepaxti in patients with relapsed or refractory multiple myeloma. These findings, derived from the OCEAN and HORIZON studies, highlight Pepaxti’s potential as a significant treatment option for patients who may not have access to novel immunotherapies, demonstrating its ability to deliver sustained benefits and durable remissions in real-world settings.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB has issued warrants to fulfill its obligations under a loan agreement with the European Investment Bank (EIB). This move involves a total of 2,788,416 warrants entitling the EIB to 3,383,326 ordinary shares, which will increase the company’s share capital by approximately SEK 375,925.13. The decision, authorized by the board of directors, allows Oncopeptides to meet its contractual obligations and potentially strengthens its financial position, impacting its operations and stakeholder interests.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB has announced a change in the number of shares and votes following a rights issue, which concluded on September 15, 2025. The total number of shares now stands at 272,706,357, with a share capital increase of SEK 5,216,392.878513. This change reflects the company’s ongoing financial adjustments to support its operations and strategic goals in the biotech industry.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB announced the successful completion of its rights issue, which was oversubscribed by approximately 157 percent, raising around SEK 150 million. This financial boost is expected to enhance the company’s operational capabilities and strengthen its market position, with new shares set to begin trading on Nasdaq Stockholm by late September 2025.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB has announced the publication of real-world evidence abstracts on its drug Pepaxti, presented at the International Myeloma Society Annual Meeting. The studies from Spain and Italy confirm Pepaxti’s efficacy and safety in treating relapsed or refractory multiple myeloma, even in heavily pretreated patients. The results highlight Pepaxti’s effectiveness and tolerability, providing valuable insights for clinicians and payers in making treatment decisions based on real-world evidence.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB has announced a new share issue with preferential rights for existing shareholders, aiming to raise approximately SEK 150 million. The disclosure document for this rights issue has been registered with the Swedish Financial Supervisory Authority and is available on the company’s website. This move is part of the company’s strategy to strengthen its financial position and support its ongoing development of cancer therapies, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB has announced a partially guaranteed rights issue of approximately SEK 150 million to support the commercialization of its cancer therapy, Pepaxti, in Europe and to advance its pre-clinical assets. The company is also progressing in partnership negotiations with Japanese pharmaceutical companies for the licensing of Pepaxti in Japan, with advanced discussions and non-binding offers received from potential partners. This strategic move aims to ensure financial stability and expand market reach, potentially leading to significant growth opportunities.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB reported a strong performance in the second quarter of 2025, with net sales reaching SEK 19.2 million, marking a 135% increase compared to the same period last year. The company attributes this growth to robust organic growth in Germany and faster-than-expected market access in Spain and Italy. Significant developments include the inclusion of their drug Pepaxti in European treatment guidelines for multiple myeloma and the lifting of a clinical hold by the U.S. FDA. These achievements are expected to enhance Oncopeptides’ market position and support its goal of reaching profitability by the end of 2026.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
Oncopeptides AB announced it will release its second-quarter 2025 financial report on August 21, 2025, followed by a webcast and Q&A session for investors, analysts, and media. This event will be led by CEO Sofia Heigis and CFO Henrik Bergentoft, providing insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.